BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. BCBS of Michigan and Cambia's Regenc ...

Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disord ...

MALVERN, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the national launch of the Better Me Provider (BMP) program, pioneering new standards in patient care and responsiveness to improve treatment accessibility within the mental health industry. The providers participating in the program are committed t ...

"The Better Me Provider Program is an approach that considers the entire patient journey, providing an optimal experience to get the help they need faster," stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. "We are excited for more NeuroStar providers to participate in the program and continue to make our lifechanging treatment more accessible to the 29 million people suffering from MDD, OCD, and anxious depression." Improved response times: Participating practices raised the bar for response ...

The following data will be presented: The Impact of Treatment Gaps on Effectiveness of Transcranial Magnetic Stimulation in MDD Presented by: Sonder Behavioral Health & Wellness, Minnetonka, Minnesota Overview: This study will showcase feasibility, safety, and efficacy results using NeuroStar with a pragmatic accelerated TMS protocol without the need for neuroimaging. Presentation Date: June 14th at 4:00 PM BST Presenter: Dr. Kenneth Pages, Medical Director of TMS of South Tampa Overview: Dr. Pages will con ...

Company Overview - Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients suffering from neurohealth disorders [4] - NeuroStar Advanced Therapy is a non-drug, noninvasive treatment indicated for major depressive disorder (MDD) and is FDA-cleared for adolescents aged 15-21 with MDD [6] - NeuroStar has delivered over 6.4 million treatments, establishing itself as the leading TMS treatment for MDD in adults [6] Industry Participation - Neuronetics is participating in the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London from June 13th-15th, showcasing six posters and one oral presentation featuring data generated using the NeuroStar TMS System [4] - The company will exhibit at booth 303 during the event [4] Research Presentations - Dr. Linda Carpenter will present data on the impact of deviations in TMS treatment timing on effectiveness [2] - Dr. Paul E. Croarkin will discuss data leading to NeuroStar's latest FDA clearance for treating adolescents as a first-line adjunct treatment for MDD [2] - Dr. Harold Sackeim will explain how early improvement can predict potential responders to treatment in his presentation [5] - Dr. Hutton will identify the impact of TMS on individual symptom domains of MDD using PHQ-9 and QIDS-SR16 scales [6]

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast. Neuronetics, Inc. believes that ment ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was $17.4 million, a 12% increase from $15.5 million in Q1 2023, primarily driven by increased treatment session sales [6][91] - U.S. Treatment Session revenue reached a record $13 million, reflecting a 22% year-over-year increase, attributed to strong performance in the local consumable customer segment [7][100] - Gross margin improved to 75.1% from 73.3% in the prior year, an increase of 180 basis points, driven by a higher mix of treatment session revenue [9] - Operating expenses decreased by 7% to $20 million compared to $21.3 million in Q1 2023, due to prudent cost management [10] - Net loss for Q1 2024 was $7.9 million, or $0.27 per share, an improvement from a net loss of $10.5 million, or $0.38 per share, in the prior year [11] Business Line Data and Key Metrics Changes - U.S. NeuroStar Advanced Therapy System revenue was $3.3 million with 41 systems shipped during the quarter, slightly below the target of 45 to 50 systems [6][92] - Revenue per active site increased to approximately $11,300 from $9,700 in the prior year, reflecting ongoing success in commercial initiatives [7][8] Market Data and Key Metrics Changes - The total addressable market for Major Depressive Disorder (MDD) has increased by approximately 35% due to the recent adolescent indication approval [3] - The adolescent patient population is estimated to impact around 4.3 million patients in the U.S., with increasing prevalence since the COVID-19 pandemic [2] Company Strategy and Development Direction - The company is focused on expanding its commercial partnerships and increasing access to NeuroStar therapy, particularly targeting the adolescent market [4][98] - The Better Me Guarantee Provider Program aims to enhance patient care and responsiveness, with plans to expand participation to over 300 sites [15][102] - The company anticipates significant media coverage and interest from the adolescent psychiatric community, expecting material impact in 2025 [23][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to profitability and cash flow positivity by Q4 2024, despite current challenges from the Change Healthcare cybersecurity incident [12][13] - The company expects Q2 revenues to be between $18 million and $19 million, with a rebound anticipated once the cybersecurity issues are resolved [14][30] Other Important Information - The company has received its eighth FDA 510(k) clearance for NeuroStar as a first-line adjunct treatment for adolescents aged 15 to 21 suffering from MDD [79] - The Better Me Guarantee Provider sites are seeing significant improvements in patient follow-up and treatment initiation times, indicating the program's effectiveness [75][76] Q&A Session Summary Question: Why maintain flat guidance despite strong treatment revenues? - Management cited uncertainty due to the cyber breach impacting system sales, leading to cautious guidance [28][30] Question: Anticipated headwinds in Q2? - Management estimated a $3 million shortfall in collections due to the cybersecurity issue, impacting cash flow [35] Question: Impact of adolescent approval on marketing spend? - Marketing spend will remain consistent, with more efficient allocation towards the Better Me Guarantee Program [64][65] Question: Trends in treatment sales growth? - Management noted strong growth in treatment sessions, with the Better Me Guarantee Program contributing positively [52][56] Question: Will the statistics for participants in the programs improve over time? - Yes, participants in the Better Me Guarantee Program continue to show improved metrics over time [57][59]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation ...

Exhibit 99.1 Neuronetics Reports Record First Quarter 2024 Financial and Operating Results MALVERN, PA., May 7, 2024 – Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights "Neuronetics had a ...